Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

被引：0
|
作者：
Steven B. Zeliadt
David F. Penson
机构：
[1] Fred Hutchinson Cancer Research Center,Division of Public Health Sciences
[2] Keck School of Medicine,Departments of Urology and Preventive Medicine
[3] University of Southern California,undefined
[4] Departments of Urology,undefined
来源：
PharmacoEconomics | 2007年 / 25卷
关键词：
Prostate Cancer; Androgen Deprivation Therapy; Flutamide; Advanced Prostate Cancer; Goserelin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease. We identified 58 articles addressing economic issues related to metastatic prostate cancer.
引用
收藏
页码：309 / 327
页数：18
相关论文
共 50 条
  • [1] Pharmacoeconomics of available treatment options for metastatic prostate cancer
    Zeliadt, Steven B.
    Penson, David F.
    [J]. PHARMACOECONOMICS, 2007, 25 (04) : 309 - 327
  • [2] Metastatic Prostate Cancer: Treatment Options
    Achard, Verane
    Putora, Paul Martin
    Omlin, Aurelius
    Zilli, Thomas
    Fischer, Stefanie
    [J]. ONCOLOGY, 2021, : 48 - 59
  • [3] Expanding Treatment Options for Metastatic Prostate Cancer
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21): : 2055 - 2058
  • [4] New treatment options for patients with metastatic prostate cancer
    Snoeks, L. L.
    Ogilvie, A. C.
    van Haarst, E. P.
    Siegert, C. E. H.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 290 - 294
  • [5] Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
    William D. Figg
    Erwin A. Kruger
    Douglas K. Price
    Sonia Kim
    William D. Dahut
    [J]. Investigational New Drugs, 2002, 20 : 183 - 194
  • [6] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    [J]. LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [7] Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
    Choudhury, Atish D.
    [J]. ONCOLOGY-NEW YORK, 2022, 36 (03): : 184 - 185
  • [8] Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
    Chakravarty, Dimple
    Huang, Li
    Kahn, Matthew
    Tewari, Ashutosh K.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2020, 47 (04) : 487 - 510
  • [9] Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer
    Figg, WD
    Kruger, EA
    Price, DK
    Kim, S
    Dahut, WD
    [J]. INVESTIGATIONAL NEW DRUGS, 2002, 20 (02) : 183 - 194
  • [10] Prostate cancer treatment options (observation versus prostatectomy) - the available evidence
    Hegarty, Josephine
    Walsh, Ella
    [J]. INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2007, 1 (03) : 99 - 111
12345